Milk Thistle (Silymarin) — Frequently Asked Questions
This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer
Frequently Asked Questions
How long does milk thistle take to lower liver enzymes?
How long does milk thistle take to lower liver enzymes?
Most clinical trials show measurable reductions in ALT and AST within 4-8 weeks of consistent daily supplementation at 420mg silymarin. However, meaningful clinical improvement in liver conditions typically requires 3-6 months of continuous use. If you are monitoring liver enzymes, retest after 8-12 weeks of supplementation.
Is milk thistle safe for daily long-term use?
Is milk thistle safe for daily long-term use?
Yes, milk thistle has an excellent safety profile even with long-term use. Clinical trials lasting up to 41 months have reported no serious adverse effects. The most common side effects are mild GI symptoms (loose stools, bloating) in about 2-10% of users. It is one of the few herbal supplements with a well-established safety record in both healthy individuals and those with liver disease.
Should I take milk thistle as a standardized extract or phytosome form?
Should I take milk thistle as a standardized extract or phytosome form?
The phytosome form (silymarin-phosphatidylcholine complex, sold as Siliphos or Meriva) delivers 4-10x more silybin to the bloodstream compared to standard extracts. If you are taking milk thistle for active liver support, the phytosome form is recommended. For general prevention, a standardized extract (70-80% silymarin) at adequate doses is effective and more affordable.
References
- Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B (1989). Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. Journal of Hepatology. DOI PubMed
- Saller R, Meier R, Brignoli R (2001). The use of silymarin in the treatment of liver diseases. Drugs. DOI PubMed
- Zhong S, Fan Y, Yan Q, Fan X, Wu B, Han Y, Zhang Y, Chen Y, Zhang H, Niu J (2017). The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials. Medicine. DOI PubMed
- Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, Graf TN, Oberlies NH (2010). Identification of hepatoprotective flavonolignans from silymarin. Proceedings of the National Academy of Sciences. DOI PubMed